Dr. Chung on a Joint Analysis of Immunotherapy Trials in SCLC

Hyun C. Chung, MD, PhD
Published: Friday, Apr 26, 2019



Hyun C. Chung, MD, PhD, professor at Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, Republic of Korea, discusses a joint analysis of the KEYNOTE-028 and KEYNOTE-158 trials in patients with advanced small cell lung cancer (SCLC).

In the phase Ib KEYNOTE-028 trial, investigators observed activity with pembrolizumab (Keytruda) monotherapy in patients with pretreated SCLC. However, it was unclear whether the benefit of the PD-1 inhibitor was restricted to patients with PD-L1 positivity, says Chung. As such, investigators looked to the KEYNOTE-158 trial, which examined the agent in patients irrespective of PD-L1 expression.

All patients in the joint analysis had received at least 2 prior lines of therapy for advanced disease. Of 131 patients enrolled in both trials, 83 were eligible for evaluation in the joint analysis. Data showed that approximately 10% of patients experienced durable responses with pembrolizumab monotherapy in the third-line, irrespective of PD-L1 status. Additional data indicated that the objective response rate was 19.3%, which included 2 complete responses and 14 partial responses.
SELECTED
LANGUAGE


Hyun C. Chung, MD, PhD, professor at Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, Republic of Korea, discusses a joint analysis of the KEYNOTE-028 and KEYNOTE-158 trials in patients with advanced small cell lung cancer (SCLC).

In the phase Ib KEYNOTE-028 trial, investigators observed activity with pembrolizumab (Keytruda) monotherapy in patients with pretreated SCLC. However, it was unclear whether the benefit of the PD-1 inhibitor was restricted to patients with PD-L1 positivity, says Chung. As such, investigators looked to the KEYNOTE-158 trial, which examined the agent in patients irrespective of PD-L1 expression.

All patients in the joint analysis had received at least 2 prior lines of therapy for advanced disease. Of 131 patients enrolled in both trials, 83 were eligible for evaluation in the joint analysis. Data showed that approximately 10% of patients experienced durable responses with pembrolizumab monotherapy in the third-line, irrespective of PD-L1 status. Additional data indicated that the objective response rate was 19.3%, which included 2 complete responses and 14 partial responses.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x